Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report

Advanced hepatocellular carcinoma (HCC) is a highly lethal disease, mainly due to the late stage at diagnosis and its rapid progression. Although patients with advanced HCC can choose targeted therapy or chemotherapy, overall, the treatment response rate is extremely low and the average survival tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chenxi, Shao, Jie, Dong, Yanbing, Xu, Qiuping, Zou, Zhengyun, Chen, Fangjun, Yan, Jing, Liu, Juan, Li, Shuangshuang, Liu, Baorui, Shen, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315135/
https://www.ncbi.nlm.nih.gov/pubmed/34326839
http://dx.doi.org/10.3389/fimmu.2021.685126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315135/
https://www.ncbi.nlm.nih.gov/pubmed/34326839
http://dx.doi.org/10.3389/fimmu.2021.685126

Ejemplares similares